RecruitingEarly Phase 1

Human Umbilical Cord Mesenchymal Stem Cells Treatment in Sepsis

China180 participantsStarted 2025-05-22

Plain-language summary

The primary objective: To evaluate the efficacy of intravenous infusion of universal UC-MSCs and CD83+MSCs subpopulation injection in the treatment of sepsis by using the 28-day survival rate of the subjects as the primary efficacy criterion.The secondary objectives: 1. To systematically evaluate the safety of universal UC-MSCs and CD83+MSCs subpopulation in the treatment of sepsis; 2. To provide theoretical basis and clinical research data for establishing a safe, effective and feasible clinical treatment plan for sepsis using stem cells.

Who can participate

Age range0 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. History of chronic enteritis, neuropsychiatric disorders, or transplantation (bone marrow, lung, liver, pancreas, or small intestine)
✕. Severe primary diseases affecting survival (e.g., life-limiting hepatic, renal, or endocrine disorders) or psychiatric disorders
✕. History of hypersensitivity or severe adverse reactions to biological products
✕. Imminent terminal status (e.g., septic shock, life expectancy \<7 days)
✕. Foreseeable risk of medical errors or disputes during hospitalization
✕. Active drug-resistant infections
✕. History of malignancy at screening
✕. Pregnancy, lactation, or plans for pregnancy within the next year

What they're measuring

28-day survival rate

Timeframe: 28 days

Trial details

NCT IDNCT06882811

SponsorDaping Hospital and the Research Institute of Surgery of the Third Military Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12-31

Contact for this trial

Xiang Xu, Professor

+8613637843870 xiangxu@tmmu.edu.cn

View on ClinicalTrials.gov More Sepsis trials